(Note: This is not an IPO. This is a NASDAQ uplisting – a unit offering – under proposed symbol “SYTA” for the stock and “SYTAW” for the warrant. From the prospectus: “Our common shares are currently trading on the TSX Venture Exchange (the “TSXV”) under the symbol “SIM”, the OTCQX under the symbol “SYATF,” and the […]

We operate the largest pet-focused online retail business in China’s pet market in terms of GMV in 2019, according to Frost & Sullivan, seamlessly connecting over 410 brand partners with pet parents in China since our inception and up to June 30, 2020. Over 10 years ago, we set out to build Boqii with the simple goal of connecting China’s […]

We may pursue an initial business combination in any business or industry but expect to focus on a target in an industry where we believe our management team and founder’s expertise will provide us with a competitive advantage. Our sponsor, Churchill Sponsor V LLC, a Delaware limited liability company, is an affiliate of M. Klein and Company. […]

We are an innovative clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. We believe our approach has the potential to fundamentally transform the therapeutic modulation of the immune system. Compounds derived from our proprietary Agonist Redirected Checkpoint, or ARC®, platform simultaneously inhibit checkpoint molecules and […]

We are a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. We are initially developing our wholly owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia, or […]

We are a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Our lead product candidate, entospletinib […]

  We intend to focus our search for a target business in the value-added distribution, industrial specialty services, and differentiated manufacturing sectors. (Note: This SPAC deal was increased in size to 11 million units, up from 10 million, at $10 each to trade on the NASDAQ, according to an SEC filing on Oct. 22, 2020.)

We intend to capitalize on the expertise of our management team in the sports (including sports franchises or assets related to sports franchises, and sports technology), entertainment and brands sectors. We intend to focus on leading sports, entertainment and brand companies that have potential for brand and commercial growth with enterprise values between $300 million […]

We intend to initially focus on companies in the travel, hospitality, leisure, financial technology (fintech), insurance technology and property technology (PropTech) sectors. We believe that the dislocation caused by the coronavirus (COVID-19) pandemic will create significant value opportunities in these sectors.

We intend to focus our efforts for an initial business combination within the broader food and consumer products value chain, where significant technology innovation is occurring from accelerating eCommerce demand trends and disruption in supply chain logistics. (The prospectus notes the impact of the COVID-19 pandemic on consumers’ buying habits and the resulting disruption of […]